Background: Cardiovascular damage is clinically manifested as coronary artery disease, heart failure, stroke and peripheral artery disease. The prevalence of these adverse conditions is higher with advancing age. Although many patients present cardiovascular damage late in their life, it is common to see patients with early atherosclerosis in cardiovascular intensive care units at ages lower than 50 years in men and 55 for women.Methods and results: In this review of the literature we identified risk factors of early vascular damage. The classic risk factors such as age, gender, diabetes mellitus, dyslipidemia, smoking, alcohol, hypertension, obesity, family history and newer biomarkers such as hs-CRP, folic acid, homocysteine, fibrinogen are neither strong nor predictive of the individual patient’s risk to present early cardiovascular disease. All these risk factors have been used to propose risk scores for possible future events but we still lack a single strong marker indicating new onset of disease that will predict the future independently of the classical factors. The role of vascular imaging techniques to identify patients with subclinical atherosclerotic vascular damage before clinical disease, including the effect of known and unknown risk factors on the vascular tree, seems to be very important for intensifying preventive measures in high risk patients. Early arteriosclerosis measured from pulse wave velocity is associated with reduced arterial elasticity and is associated with future cardiovascular events. Conclusions: Vascular measurements may better represent the continuum of cardiovascular disease from a young healthy to an aged diseased vessel that is going to produce adverse clinical events.
Keywords: Arterial stiffness, intima media thickness, early vascular aging, early arteriosclerosis, early atherosclerosis, cardiovascular disease.
Development and Characterization of Metformin Loaded Pectin Nanoparticles for T2 Diabetes Mellitus
Pharmaceutical Nanotechnology The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets The Impact of the Emerging Genomics Data on the Management of Agerelated Phenotypes in the Context of Cellular Senescence
Current Drug Targets Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry New Horizons in Diabetes Therapy: The Angiogenesis Paradox in Diabetes: Description of the Problem and Presentation of a Unifying Hypothesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis The Clinical Relevance of Advanced Glycation Endproducts (AGE) and Recent Developments in Pharmaceutics to Reduce AGE Accumulation
Current Medicinal Chemistry Attenuating Diabetes: What Really Works?
Current Diabetes Reviews The Contrast Sensitivity Test in Early Detection of Ocular Changes in the Relation to the Type I Diabetes Mellitus Compensation in Children,Teenagers, and Young Adults
Recent Patents on Inflammation & Allergy Drug Discovery Baupain, A Plant Cysteine Proteinase That Hinders Thrombin-Induced Human Platelet Aggregation
Protein & Peptide Letters Estrogen Receptor 1 Agonist PPT Stimulates Slc2a4 Gene Expression and Improves Insulin-Induced Glucose Uptake in Adipocytes
Current Topics in Medicinal Chemistry The Role of Carbonic Anhydrase in Hepatic Glucose Production
Current Diabetes Reviews Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision
Current Cardiology Reviews Mechanisms Involved in Glycemic Control Promoted by Exercise in Diabetics
Current Diabetes Reviews Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews IL-1β and IL-1Ra Variant Profiles in Turkish Patients with Diabetic Peripheral Neuropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyphenols in Disease: from Diet to Supplements
Current Pharmaceutical Biotechnology